After scaling back operations last year by cutting jobs and pausing its fungus-based discovery platform to conserve cash for its lead program, LifeMine Therapeutics is reviving that technology with fresh backing that includes major investments from Jeff Bezos and Bill Gates.
The Massachusetts biotech also disclosed that it had quietly completed a $75 million Series D financing in November 2025, led primarily by existing investors such as Google Ventures and GSK. More recently, Chief Executive Officer Gregory Verdine met separately with Bezos and Gates to present the company’s drug discovery platform.
Gates’ and Bezos’ Reactions
Verdine said both investors strongly encouraged LifeMine to restart the platform and expressed interest in investing significantly more capital than the company ultimately chose to raise.
The enthusiasm from the two billionaires helped drive a $188 million Series E financing, which Verdine said was three to four times larger than LifeMine had initially planned. RA Capital Management also joined the round as a new investor.
How the Discovery Platform Works
LifeMine’s discovery platform is built on genetic sequencing data from 100,000 fungal strains. The company has organized those genes into clusters according to their biosynthetic pathways, creating a resource that has identified approximately 1,200 potential drug targets. Verdine said the company plans to begin deploying AI agents within the next month to analyze those targets and uncover promising therapeutic candidates.
According to Verdine, the breadth of potential applications across multiple disease areas creates exceptional opportunities for partnerships and licensing agreements. He noted that LifeMine has already established a productive relationship with investor GSK, although a previous drug discovery collaboration between the companies has slowed after GSK shifted its internal priorities.
Verdine added that he would not be surprised to see a renewed collaboration with GSK in the future, citing the strong relationship between the two companies.
The Firm’s Current Focus
For now, however, the company’s primary focus remains LIFE-001, a next-generation immunosuppressive therapy that targets the T-cell-activating enzyme calcineurin. Existing calcineurin inhibitors are widely used following organ transplantation to prevent immune rejection but are associated with significant toxicity.
Verdine said LIFE-001 has maintained the efficacy associated with calcineurin inhibition while eliminating the toxicity typically seen with existing therapies, adding that the treatment has already demonstrated those characteristics in more than 100 healthy volunteers receiving therapeutic doses. He explained that the therapy achieves this by inhibiting calcineurin before the enzyme becomes activated.
LifeMine’s Future Plans
LifeMine plans to begin a Phase 1b trial early next year involving 12 patients undergoing islet cell transplantation, alongside a larger Phase 2 study enrolling 150 kidney transplant recipients that will compare LIFE-001 with tacrolimus. The company expects results from both studies in 2027.
Verdine also said the opportunity in organ transplantation alone is substantial, estimating that LIFE-001 could generate between $25 billion and $30 billion in annual revenue if it ultimately reaches the market. He added that LifeMine also plans to expand the development of LIFE-001 beyond transplantation, with the company ultimately aiming to evaluate the therapy in autoimmune diseases, most likely treatment-resistant ulcerative colitis.
LifeMine is attracting attention across the biotechnology sector as it advances a new approach to drug discovery. The company is building its platform around evolutionary insights from fungi, human genetics, genomics, bioinformatics, machine learning, and synthetic biology.
The company previously raised $175 million in Series C financing, with funding intended to advance its proprietary Avatar-Rx platform and move multiple drug candidates toward the clinic. Investors in that round included Fidelity Management & Research Company, Invus, 3W Partners Capital, GSK, GV, Arch Venture Partners, Blue Pool Capital, and MRL Ventures Fund.
Why LifeMine Is Getting Attention
LifeMine is pursuing what it calls Top-Down Drug Discovery, using evolutionary information from fungi to identify genetically encoded small molecules that could become new medicines. This strategy is designed to address difficult-to-drug biological targets and expand the range of molecules available to drug developers.
